Symbols / IVVD
IVVD Chart
About
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 476.56M |
| Enterprise Value | 311.69M | Income | -59.86M | Sales | 50.04M |
| Book/sh | 0.43 | Cash/sh | 0.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | 99 | IPO | — |
| P/E | — | Forward P/E | -12.52 | PEG | — |
| P/S | 9.52 | P/B | 3.89 | P/C | — |
| EV/EBITDA | -5.15 | EV/Sales | 6.23 | Quick Ratio | 2.14 |
| Current Ratio | 2.47 | Debt/Eq | 2.88 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.14 | EPS Growth | — |
| Revenue Growth | 41.20% | Earnings | 2026-03-19 | ROA | -25.84% |
| ROE | -67.94% | ROIC | — | Gross Margin | 93.34% |
| Oper. Margin | -83.96% | Profit Margin | -119.63% | Shs Outstand | 281.99M |
| Shs Float | 138.05M | Short Float | 9.58% | Short Ratio | 6.81 |
| Short Interest | — | 52W High | 3.07 | 52W Low | 0.46 |
| Beta | 0.60 | Avg Volume | 3.77M | Volume | 1.09M |
| Target Price | $10.00 | Recom | None | Prev Close | $1.61 |
| Price | $1.69 | Change | 4.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.69
Latest analyst target
3. DCF / Fair value
$-2.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.69
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | reit | BTIG | Buy → Buy | $10 |
| 2025-12-22 | init | BTIG | — → Buy | $10 |
| 2025-11-25 | down | D. Boral Capital | Buy → Hold | — |
| 2025-11-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-31 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-06 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-06 | init | Cantor Fitzgerald | — → Overweight | $10 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-25 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-08-19 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-06-26 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-05-28 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-05 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-02-24 | main | D. Boral Capital | Buy → Buy | $9 |
- New study maps COVID protection to antibody levels, not variants - Stock Titan ue, 24 Feb 2026 12
- Insider Sale: Chief Scientific Officer of $IVVD Sells 18,189 Shares - Quiver Quantitative hu, 19 Feb 2026 02
- How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance Sat, 24 Jan 2026 08
- Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com hu, 19 Feb 2026 02
- Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail Wed, 04 Feb 2026 08
- Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st hu, 29 Jan 2026 08
- Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com Nigeria hu, 19 Feb 2026 05
- Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- Invivyd (Nasdaq: IVVD) starts underwritten common stock sale with 30-day 15% option - Stock Titan Mon, 17 Nov 2025 08
- $IVVD stock is up 25% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Dec 2025 08
- ​Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 - Yahoo Finance Wed, 14 Jan 2026 08
- $IVVD stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect - Yahoo Finance Wed, 05 Nov 2025 08
- Invivyd, Inc. Stock (IVVD) Opinions on Q3 2025 Financial Results and FDA Clearance - Quiver Quantitative Fri, 14 Nov 2025 08
- $IVVD stock is up 27% today. Here's what we see in our data. - Quiver Quantitative Mon, 06 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | DUKE WILLIAM E. JR. | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 67710 | 105581.0 | — | Sale at price 1.54 - 1.58 per share. | ANDERSEN JILL | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 37581 | 58600.0 | — | Sale at price 1.54 - 1.58 per share. | ALLEN ROBERT D III | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | GREEN JULIE | Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | LEE EDWARD TIMOTHY | Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 99000 | nan | — | — | DUKE WILLIAM E. JR. | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 165000 | nan | — | — | ANDERSEN JILL | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 99000 | nan | — | — | ALLEN ROBERT D III | Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 99000 | nan | — | — | GREEN JULIE | Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 99000 | nan | — | — | LEE EDWARD TIMOTHY | Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -173.76M | -200.78M | -204.02M | -211.91M |
| TotalUnusualItems | 0.00 | -4.97M | -21.77M | -7.50M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -4.97M | -21.77M | -7.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -169.93M | -198.64M | -241.32M | -226.79M |
| ReconciledDepreciation | 3.11M | 2.03M | 462.00K | 1.00K |
| ReconciledCostOfRevenue | 1.62M | 0.00 | ||
| EBITDA | -173.76M | -205.75M | -225.80M | -219.41M |
| EBIT | -176.88M | -207.78M | -226.26M | -219.41M |
| NormalizedIncome | -169.93M | -193.67M | -219.54M | -219.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -169.93M | -198.64M | -241.32M | -226.79M |
| TotalExpenses | 202.26M | 207.78M | 226.26M | 219.41M |
| TotalOperatingIncomeAsReported | -176.88M | -212.76M | -248.03M | -226.91M |
| DilutedAverageShares | 118.56M | 109.53M | 108.27M | 42.62M |
| BasicAverageShares | 118.56M | 109.53M | 108.27M | 42.62M |
| DilutedEPS | -1.43 | -1.81 | -2.23 | -5.32 |
| BasicEPS | -1.43 | -1.81 | -2.23 | -5.32 |
| DilutedNIAvailtoComStockholders | -169.93M | -198.64M | -241.32M | -226.79M |
| NetIncomeCommonStockholders | -169.93M | -198.64M | -241.32M | -226.79M |
| NetIncome | -169.93M | -198.64M | -241.32M | -226.79M |
| NetIncomeIncludingNoncontrollingInterests | -169.93M | -198.64M | -241.32M | -226.79M |
| NetIncomeContinuousOperations | -169.93M | -198.64M | -241.32M | -226.79M |
| PretaxIncome | -169.93M | -198.64M | -241.32M | -226.79M |
| OtherIncomeExpense | 6.95M | 9.14M | -15.06M | -7.38M |
| OtherNonOperatingIncomeExpenses | 6.95M | 14.12M | 6.71M | 118.00K |
| SpecialIncomeCharges | 0.00 | -4.97M | -4.40M | -7.50M |
| OtherSpecialCharges | 4.97M | 4.40M | 7.50M | |
| GainOnSaleOfSecurity | -17.37M | |||
| OperatingIncome | -176.88M | -207.78M | -226.26M | -219.41M |
| OperatingExpense | 200.64M | 207.78M | 226.26M | 219.41M |
| ResearchAndDevelopment | 137.25M | 158.66M | 179.21M | 182.89M |
| SellingGeneralAndAdministration | 63.39M | 49.12M | 47.04M | 36.52M |
| GeneralAndAdministrativeExpense | 63.39M | 49.12M | 47.04M | 36.52M |
| OtherGandA | 33.48M | 21.80M | 25.89M | 16.98M |
| SalariesAndWages | 29.91M | 27.32M | 21.15M | 19.54M |
| GrossProfit | 23.77M | 0.00 | ||
| CostOfRevenue | 1.62M | 0.00 | ||
| TotalRevenue | 25.38M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 25.38M | 0.00 | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 468.75K | ||
| OrdinarySharesNumber | 119.84M | 110.16M | 109.04M | 110.78M |
| ShareIssued | 119.84M | 110.16M | 109.04M | 111.25M |
| TotalDebt | 1.30M | 2.17M | 3.72M | 0.00 |
| TangibleBookValue | 67.54M | 177.47M | 355.97M | 558.02M |
| InvestedCapital | 67.54M | 177.47M | 355.97M | 558.02M |
| WorkingCapital | 38.70M | 174.59M | 351.89M | 554.65M |
| NetTangibleAssets | 67.54M | 177.47M | 355.97M | 558.02M |
| CapitalLeaseObligations | 1.30M | 2.17M | 3.72M | 0.00 |
| CommonStockEquity | 67.54M | 177.47M | 355.97M | 558.02M |
| TotalCapitalization | 67.54M | 177.47M | 355.97M | 558.02M |
| TotalEquityGrossMinorityInterest | 67.54M | 177.47M | 355.97M | 558.02M |
| StockholdersEquity | 67.54M | 177.47M | 355.97M | 558.02M |
| GainsLossesNotAffectingRetainedEarnings | -5.00K | -13.00K | -272.00K | -8.00K |
| OtherEquityAdjustments | -5.00K | -13.00K | -272.00K | -8.00K |
| TreasuryStock | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -901.99M | -732.07M | -533.43M | -292.11M |
| AdditionalPaidInCapital | 969.53M | 909.54M | 889.66M | 850.12M |
| CapitalStock | 12.00K | 11.00K | 11.00K | 11.00K |
| CommonStock | 12.00K | 11.00K | 11.00K | 11.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 61.98M | 51.71M | 27.20M | 62.07M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.42M | 2.17M | 12.00K |
| OtherNonCurrentLiabilities | 700.00K | 1.00K | 12.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DuetoRelatedPartiesNonCurrent | 0.00 | 700.00K | ||
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 722.00K | 2.17M | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 722.00K | 2.17M | 0.00 |
| CurrentLiabilities | 61.98M | 50.29M | 25.03M | 62.06M |
| OtherCurrentLiabilities | 27.00K | 35.00K | 44.00K | |
| CurrentDebtAndCapitalLeaseObligation | 1.30M | 1.44M | 1.56M | |
| CurrentCapitalLeaseObligation | 1.30M | 1.44M | 1.56M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.92M | 10.75M | 5.99M | 4.95M |
| PayablesAndAccruedExpenses | 56.73M | 38.06M | 17.44M | 57.12M |
| CurrentAccruedExpenses | 46.28M | 30.11M | 15.93M | 51.33M |
| Payables | 10.45M | 7.95M | 1.52M | 5.78M |
| AccountsPayable | 10.45M | 7.95M | 1.52M | 5.78M |
| TotalAssets | 129.51M | 229.18M | 383.17M | 620.09M |
| TotalNonCurrentAssets | 28.83M | 4.30M | 6.25M | 3.38M |
| OtherNonCurrentAssets | 25.94M | 175.00K | 191.00K | 3.30M |
| NetPPE | 2.89M | 4.12M | 6.06M | 83.00K |
| GrossPPE | 2.89M | 4.12M | 6.06M | 83.00K |
| OtherProperties | 2.89M | 4.12M | 6.06M | 83.00K |
| CurrentAssets | 100.68M | 224.88M | 376.92M | 616.71M |
| PrepaidAssets | 20.16M | 23.31M | 4.55M | 25.06M |
| Receivables | 11.17M | 933.00K | 377.00K | 229.00K |
| AccruedInterestReceivable | 263.00K | 933.00K | 377.00K | 229.00K |
| AccountsReceivable | 10.91M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 69.35M | 200.64M | 371.99M | 591.42M |
| OtherShortTermInvestments | 0.00 | 279.92M | 49.19M | |
| CashAndCashEquivalents | 69.35M | 200.64M | 92.08M | 542.22M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -170.63M | -173.78M | -221.69M | -184.82M |
| RepurchaseOfCapitalStock | 0.00 | -1.00K | -4.00K | 0.00 |
| IssuanceOfCapitalStock | 39.28M | 0.00 | 0.00 | 666.07M |
| CapitalExpenditure | -140.00K | -615.00K | -1.71M | -84.00K |
| EndCashPosition | 69.35M | 200.64M | 92.08M | 542.22M |
| BeginningCashPosition | 200.64M | 92.08M | 542.22M | 114.99M |
| EffectOfExchangeRateChanges | 8.00K | 0.00 | ||
| ChangesInCash | -131.30M | 108.56M | -450.15M | 427.24M |
| FinancingCashFlow | 39.33M | 1.04M | 506.00K | 662.68M |
| CashFlowFromContinuingFinancingActivities | 39.33M | 1.04M | 506.00K | 662.68M |
| NetOtherFinancingCharges | -597.00K | -149.00K | -3.38M | |
| ProceedsFromStockOptionExercised | 643.00K | 1.20M | 510.00K | 0.00 |
| NetPreferredStockIssuance | 0.00 | 335.16M | ||
| PreferredStockIssuance | 0.00 | 335.16M | ||
| NetCommonStockIssuance | 39.28M | -1.00K | -4.00K | 330.90M |
| CommonStockPayments | 0.00 | -1.00K | -4.00K | 0.00 |
| CommonStockIssuance | 39.28M | 0.00 | 0.00 | 330.90M |
| InvestingCashFlow | -140.00K | 280.68M | -230.67M | -50.71M |
| CashFlowFromContinuingInvestingActivities | -140.00K | 280.68M | -230.67M | -50.71M |
| NetInvestmentPurchaseAndSale | 0.00 | 281.30M | -228.96M | -50.63M |
| SaleOfInvestment | 0.00 | 372.50M | 69.00M | 138.00M |
| PurchaseOfInvestment | 0.00 | -91.20M | -297.96M | -188.63M |
| NetPPEPurchaseAndSale | -140.00K | -615.00K | -1.71M | -84.00K |
| PurchaseOfPPE | -140.00K | -615.00K | -1.71M | -84.00K |
| OperatingCashFlow | -170.49M | -173.16M | -219.99M | -184.74M |
| CashFlowFromContinuingOperatingActivities | -170.49M | -173.16M | -219.99M | -184.74M |
| ChangeInWorkingCapital | -23.47M | 5.89M | -16.13M | 22.79M |
| ChangeInOtherCurrentLiabilities | -2.37M | -869.00K | -436.00K | 1.00K |
| ChangeInOtherCurrentAssets | 141.00K | 16.00K | 3.11M | -3.30M |
| ChangeInPayablesAndAccruedExpense | 11.37M | 25.63M | -39.17M | 48.99M |
| ChangeInAccruedExpense | 8.95M | 19.16M | -34.87M | 51.36M |
| ChangeInPayable | 2.42M | 6.47M | -4.30M | -2.37M |
| ChangeInAccountPayable | 2.42M | 6.47M | -4.30M | -2.37M |
| ChangeInPrepaidAssets | 3.19M | -18.89M | 20.37M | -22.90M |
| ChangeInInventory | -24.89M | 0.00 | ||
| ChangeInReceivables | -10.91M | 0.00 | ||
| ChangesInAccountReceivables | -10.91M | 0.00 | ||
| OtherNonCashItems | 66.00K | |||
| StockBasedCompensation | 19.79M | 18.68M | 21.65M | 17.76M |
| AmortizationOfSecurities | 0.00 | -1.12M | -2.02M | 1.43M |
| DepreciationAmortizationDepletion | 3.11M | 2.03M | 462.00K | 1.00K |
| DepreciationAndAmortization | 3.11M | 2.03M | 462.00K | 1.00K |
| Depreciation | 3.11M | 2.03M | 462.00K | 1.00K |
| OperatingGainsLosses | 17.37M | |||
| GainLossOnInvestmentSecurities | 17.37M | |||
| NetIncomeFromContinuingOperations | -169.93M | -198.64M | -241.32M | -226.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IVVD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|